Assessing and Treating Clients With Anxiety Disorders

The structure of this assignment is a decision tree, and the marks are not distributed the way students expect. Each of the three decision points asks four things, and only the first — *which decision did you select* — is a choice. The other three are argument: why you selected it, what you hoped to achieve, and how the actual result differed from what you expected. That last question is the one that carries the assessment, because it is the only one that cannot be answered before you click. A paper that names three reasonable medication choices and justifies each will still score modestly if it never engages with the gap between prediction and outcome. Plan to spend most of your words there, and write the expectation down *before* you see the result so that the comparison is honest rather than reconstructed afterwards.

The brief tells you what to think about while choosing: *factors that might impact the client's pharmacokinetic and pharmacodynamic processes*. Those are two different things and conflating them is a standing error. Pharmacokinetics is what the body does to the drug — absorption, distribution, hepatic metabolism and the CYP450 pathways that matter for most anxiolytics, protein binding, renal clearance, and the age, weight, hepatic function and interacting medications that shift them. Pharmacodynamics is what the drug does to the body — receptor affinity, the serotonergic and GABAergic mechanisms at work, tolerance, and the relationship between concentration and effect. For a middle-aged adult, both are in play and neither is dramatic, so the point is to name the specific factors this client presents rather than recite the definitions. A useful discipline is to write one sentence per factor naming the factor, the mechanism it acts through, and the consequence for this prescription, because that structure makes it impossible to state a factor without saying why it matters.

Anxiety pharmacotherapy has a particular shape that your rationale should reflect. First-line treatment is an SSRI or SNRI, whose anxiolytic effect takes weeks rather than days and often begins with a transient worsening of anxiety or activation that patients may read as the drug failing. Benzodiazepines act immediately but carry dependence, tolerance and cognitive risk, which is why they are generally adjunctive or short-term. Buspirone is an option without those liabilities and with a slower onset. That timing asymmetry is the single most useful thing to understand before making decision one, because it explains why a decision that looks unsuccessful at the next visit may simply not have been given long enough — and distinguishing *insufficient time* from *insufficient dose* from *wrong drug* is exactly the clinical reasoning being assessed. Say which of those three explanations you are relying on at each decision point, because the tree usually offers an option for each and choosing between them is the reasoning the marker is reading for.

Ground your outcome claims in a measure rather than in impression. The Hamilton Anxiety Rating Scale appears in this week's resources for a reason: it turns 'the client seems better' into a score you can compare across visits, and it lets you say what magnitude of change would count as a response rather than as noise. When the case gives you a HAM-A score at a decision point, use it explicitly in the paragraph explaining what you hoped to achieve, and state the target. When the follow-up score moves less than you predicted, that is not a failure of your paper — it is the material the fourth question was written to elicit. A candid account of why your expectation was wrong reads as clinical maturity; a paper in which every decision worked exactly as intended reads as one that was written backwards from the answer.

The ethics element is a required part of the submission and is routinely treated as a closing paragraph of generalities. Anchor it to this client and to these decisions instead. Informed consent for an anxiolytic has specific content: the delay before benefit, the possibility of early activation, sexual side effects that patients frequently stop medication over without reporting, and — if a benzodiazepine is involved — dependence and the plan for stopping. Communication matters too, since a client whose physical symptoms were investigated for cardiac causes before being referred may need the psychiatric explanation handled carefully to avoid feeling dismissed. Where the decision tree offers an option that would be cheaper or faster but less well evidenced, say what makes it ethically different rather than simply not choosing it. Say who else needs to know as well, since a treatment plan involving a primary care provider who has already investigated the physical symptoms raises a real question about what is communicated back and with whose consent.

Mind the mechanics, because they are easy marks and easy losses. The brief requires a minimum of three academic resources and states explicitly that the course text does not count toward that minimum — so Stahl can support your reasoning but cannot be one of the three. Every *why* and every *what were you hoping to achieve* asks you to support the response with evidence, which means citations distributed across all three decision points rather than banked in an opening literature review. Write the decisions in the order you made them, keep the client's presentation in view rather than restating the case at length, and make sure the conclusion actually addresses ethical considerations for *treatment plan and communication*, which are two requirements sharing one sentence in the brief. Check the resource count against your reference list rather than your memory of it, because a list that looks long can still fall short once the course text and the case study itself are excluded from the total.